```html

Yolk‑Sac Liver Disease (Congenital Hepatic Fibrosis)

Overview

Yolk‑sac liver disease is another term for congenital hepatic fibrosis (CHF), a rare, inherited disorder that causes progressive scarring (fibrosis) of the liver’s tiny bile ducts and surrounding tissue. The condition is present at birth (hence “congenital”) but may not become apparent until childhood or early adulthood.

Who it affects: CHF is autosomal recessive, meaning a child must inherit two abnormal copies of a gene (one from each parent) to develop the disease. It is most frequently seen in families with consanguineous marriages and in certain ethnic groups (e.g., Arab, Turkish, and South‑Asian populations).

Prevalence: Exact worldwide numbers are uncertain because many cases remain undiagnosed, but estimates range from 1 in 20,000 to 1 in 100,000 live births (NIH, 2022). In regions with higher rates of recessive inheritance, prevalence can be severalfold greater.

Symptoms

The clinical picture varies widely. Some patients present in infancy, while others are diagnosed in their teens or even adulthood. The most common manifestations stem from portal hypertension (high pressure in the liver’s portal vein) and impaired bile‑duct function.

Hepatic (liver‑related) symptoms

• Splenomegaly: Enlarged spleen due to back‑pressure from the portal vein. Often the first sign.
• Bleeding varices: Dilated veins in the esophagus or stomach that can rupture, causing life‑threatening bleeding.
• Ascites: Accumulation of fluid in the abdomen, leading to swelling and discomfort.
• Hepatomegaly: Mild to moderate enlargement of the liver, usually non‑tender.
• Jaundice: Yellowing of skin and eyes is less common than in other liver diseases but can occur if bile flow is significantly obstructed.
• Growth retardation: Chronic illness may impair weight gain and height development in children.

Renal (kidney) involvement

About 50‑70% of patients have a co‑existing renal disorder known as ciliopathy, most commonly polycystic kidney disease (PKD) or medullary sponge kidney. Symptoms may include:

• Hypertension (high blood pressure)
• Hematuria (blood in urine)
• Decreased kidney function over time

Extra‑hepatic features

• Portal‑systemic encephalopathy: Confusion, lethargy, or abnormal behavior due to toxin buildup.
• Respiratory infections: Often related to splenomegaly‑induced immune deficiency.
• Facial dysmorphism: Some families report subtle facial features (e.g., broad nasal bridge) but this is not universal.

Causes and Risk Factors

CHF results from genetic mutations that disrupt the structure and function of primary cilia—tiny, hair‑like organelles on the surface of many cells. These cilia are crucial for signaling pathways that regulate organ development.

Key genetic causes

• PKHD1 – Mutations cause autosomal recessive polycystic kidney disease (ARPKD) and are the most common cause of CHF.
• PKD1 / PKD2 – Typically linked to adult‑onset polycystic kidney disease but can present with congenital fibrosis in rare families.
• Other ciliopathy genes – e.g., TMEM67, NPHP1, DCDC2. Ongoing research continues to identify new loci.

Risk factors

• Consanguineous parentage (first‑cousin or closer marriage).
• Family history of CHF, ARPKD, or other ciliopathies.
• Certain ethnic backgrounds (Middle Eastern, Mediterranean, South‑Asian).

Because the disease is genetic, lifestyle factors do not cause CHF, but they can influence disease progression (e.g., alcohol intake may worsen liver injury).

Diagnosis

Diagnosis relies on a combination of clinical assessment, imaging, laboratory tests, and sometimes genetic analysis.

Clinical evaluation

• Physical exam – palpation for enlarged liver/spleen; assessment for ascites.
• History – recurrent gastrointestinal bleeding, growth delay, family history.

Laboratory studies

• Complete blood count – often shows anemia or thrombocytopenia due to splenic sequestration.
• Liver function panel – transaminases may be modestly elevated; alkaline phosphatase and gamma‑GT can be high.
• Coagulation profile – prolonged PT/INR if synthetic function declines.
• Renal function – serum creatinine, electrolytes, urinalysis.

Imaging

• Ultrasound: First‑line; demonstrates enlarged echogenic liver, splenomegaly, and may detect cystic kidneys.
• Magnetic Resonance Imaging (MRI) / MRCP: Provides detailed view of bile‑duct architecture and rules out other biliary atresia.
• CT scan: Useful for evaluating varices, portal vein anatomy, and renal cyst burden.
• Transient elastography (FibroScan): Non‑invasive measurement of liver stiffness to gauge fibrosis severity.

Endoscopic assessment

Upper GI endoscopy is performed when variceal bleeding is suspected; it can also be used prophylactically to treat high‑risk varices with band ligation.

Histology (liver biopsy)

While not always required, a core needle biopsy shows characteristic "ductal plate malformation" – malformed bile ducts surrounded by fibrosis. This finding confirms the diagnosis when imaging is equivocal.

Genetic testing

Targeted gene panels or whole‑exome sequencing can identify pathogenic variants in PKHD1, PKD1, PKD2, etc. Genetic confirmation is valuable for family counseling and prenatal diagnosis.

Treatment Options

There is currently no cure; management focuses on controlling complications and preserving liver‑kidney function.

Pharmacologic therapy

• Beta‑blockers (e.g., propranolol, nadolol): Reduce portal pressure and lower risk of variceal bleeding.
• Diuretics (spironolactone ± furosemide): Manage ascites and peripheral edema.
• Octreotide or somatostatin analogues: Short‑term control of acute variceal bleeding.
• Antibiotic prophylaxis: Ciprofloxacin or ceftriaxone to prevent spontaneous bacterial peritonitis in patients with ascites.
• Vitamin K & plasma products: For coagulopathy correction before invasive procedures.

Endoscopic & interventional procedures

• Endoscopic variceal ligation (EVL): First‑line for primary and secondary prevention of variceal hemorrhage.
• Transjugular intrahepatic portosystemic shunt (TIPS): Creates a channel between portal and hepatic veins to lower portal pressure; considered when medical therapy fails.
• Percutaneous hepatic venous pressure gradient measurement: Helpful for assessing severity and TIPS candidacy.

Surgical options

• Liver transplantation: Indicated for end‑stage liver disease, refractory variceal bleeding, or hepatocellular carcinoma. Combined liver‑kidney transplantation is preferred when significant renal disease coexists.

Lifestyle & supportive measures

• Limit alcohol and avoid hepatotoxic medications (e.g., high‑dose acetaminophen).
• Maintain a balanced, low‑sodium diet to reduce ascites.
• Vaccinate against hepatitis A & B, pneumococcus, and seasonal influenza.
• Regular monitoring of blood pressure and renal function.

Living with Yolk‑Sac Liver Disease (Congenital Hepatic Fibrosis)

Although the diagnosis can be daunting, many individuals lead active lives with proper care.

Daily management tips

• Medication adherence: Use a pill organizer or set alarms to ensure beta‑blockers and diuretics are taken consistently.
• Fluid & sodium restriction: Aim for < 2 liters of fluid per day and < 2 g of sodium unless otherwise directed by your physician.
• Regular follow‑up: Liver ultrasound & elastography every 6–12 months; renal ultrasound annually.
• Nutrition: Small, frequent meals rich in protein (unless portal encephalopathy risk) and complex carbs. A dietitian experienced with liver disease can help tailor the plan.
• Physical activity: Moderate‑intensity exercise (e.g., walking, swimming) 150 minutes per week is safe for most patients and supports cardiovascular health.
• Monitor for signs of bleeding: Black/tarry stools, vomiting blood, or sudden abdominal pain warrant immediate medical attention.
• Psychosocial support: Join patient advocacy groups (e.g., National Organization for Rare Disorders) and consider counseling to address anxiety or coping challenges.

Prevention

Because CHF is genetic, primary prevention focuses on family planning and early detection.

• Genetic counseling: Recommended for couples with a known carrier or affected family member. Carrier testing can inform reproductive options (e.g., IVF with pre‑implantation genetic diagnosis).
• Prenatal screening: High‑resolution ultrasound can identify enlarged kidneys or liver early in pregnancy; amniocentesis or chorionic villus sampling can detect pathogenic mutations.
• Avoid liver injury: While it won’t prevent CHF, avoiding alcohol, illicit drugs, and unnecessary hepatotoxic medications can slow progression.

Complications

If left untreated or poorly managed, CHF can lead to serious, sometimes life‑threatening problems.

• Portal hypertension complications: Recurrent variceal bleeding, splenic infarction, and hepatic encephalopathy.
• Progressive liver failure: Ascites, jaundice, coagulopathy, and need for transplantation.
• Renal failure: Particularly when associated with ARPKD; may require dialysis or kidney transplant.
• Infections: Spontaneous bacterial peritonitis, pneumonia, or sepsis due to splenic dysfunction.
• Hepatocellular carcinoma (HCC): Though rare in CHF compared with cirrhosis from other causes, surveillance is advised for patients with cirrhotic transformation.

When to Seek Emergency Care

References

• Mayo Clinic. “Congenital hepatic fibrosis.” https://www.mayoclinic.org (accessed June 2026).
• National Institutes of Health (NIH). “Genetic and Rare Diseases Information Center – Congenital Hepatic Fibrosis.” https://rarediseases.info.nih.gov.
• Cleveland Clinic. “Portal Hypertension and Variceal Bleeding.” https://my.clevelandclinic.org.
• World Health Organization (WHO). “Guidelines for the Management of Liver Diseases.” 2023.
• European Association for Study of the Liver (EASL). “Management of Autosomal Recessive Polycystic Kidney Disease and Associated Hepatic Fibrosis.” 2022.

```